Cogent Biosciences, Inc. financial data

Symbol
COGT on Nasdaq
Industry
Pharmaceutical Preparations
Location
275 Wyman Street, 3 Rd Floor, Waltham, MA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Unum Therapeutics Inc. (to 10/5/2020), Unum Therapeutics, Inc. (to 3/30/2018)
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 915 % -20.7%
Debt-to-equity 16.1 % +5.84%
Return On Equity -67 % -18.9%
Return On Assets -57.7 % -18%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 109M shares +28.1%
Common Stock, Shares, Outstanding 109M shares +28.1%
Entity Public Float 968M USD +70.5%
Common Stock, Value, Issued 109K USD +28.2%
Weighted Average Number of Shares Outstanding, Basic 99.2M shares +32.8%
Weighted Average Number of Shares Outstanding, Diluted 99.2M shares +32.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 206M USD +45.4%
General and Administrative Expense 38.8M USD +32.3%
Costs and Expenses 245M USD +43.1%
Operating Income (Loss) -245M USD -43.1%
Nonoperating Income (Expense) 17.6M USD +29.6%
Net Income (Loss) Attributable to Parent -227M USD -44.3%
Earnings Per Share, Basic -2.49 USD/shares -16.4%
Earnings Per Share, Diluted -2.49 USD/shares -16.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 88.2M USD -58.8%
Assets, Current 370M USD +10.6%
Property, Plant and Equipment, Net 7.36M USD -19.1%
Operating Lease, Right-of-Use Asset 21.1M USD -6.28%
Other Assets, Noncurrent 4.86M USD +1.82%
Assets 430M USD +9.57%
Accounts Payable, Current 8.98M USD +25.3%
Employee-related Liabilities, Current 5.68M USD +19.3%
Liabilities, Current 40M USD +55.3%
Operating Lease, Liability, Noncurrent 16.7M USD -8.11%
Liabilities 56.7M USD +29.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -192K USD -97.9%
Retained Earnings (Accumulated Deficit) -721M USD -46%
Stockholders' Equity Attributable to Parent 373M USD +7.12%
Liabilities and Equity 430M USD +9.57%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -52.5M USD -32.9%
Net Cash Provided by (Used in) Financing Activities 214M USD +48003%
Net Cash Provided by (Used in) Investing Activities 1.04M USD -98.3%
Common Stock, Shares Authorized 300M shares +100%
Common Stock, Shares, Issued 109M shares +28.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 163M USD +681%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 88.2M USD -58.8%
Deferred Tax Assets, Valuation Allowance 157M USD +75.4%
Operating Lease, Liability 18.9M USD -4.05%
Payments to Acquire Property, Plant, and Equipment 70K USD -93.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -227M USD -44.3%
Lessee, Operating Lease, Liability, to be Paid 28M USD -8.27%
Property, Plant and Equipment, Gross 12M USD +30.8%
Operating Lease, Liability, Current 1.48M USD +25.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.84M USD +2.19%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.78M USD +9.28%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9.16M USD -13.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.7M USD -5.07%
Deferred Tax Assets, Operating Loss Carryforwards 48M USD +32.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.13M USD -20.9%
Operating Lease, Payments 873K USD +13.1%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 37M USD +63.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%